Dna Data: Life Insurance's Future?

The use of DNA information by life insurance companies is a highly debated topic. While some argue that DNA information can help life insurance companies find early signs of cancer or cardiovascular disease and suggest medical intervention, others argue that it can lead to unfair discrimination and loss of access to insurance. In the US, there is no federal law that limits the use of genetic information by life insurance companies. However, some states have laws that restrict life insurers from using genetic information. Consumers need to be aware of their rights and the potential risks of disclosing DNA information to life insurance companies.

Privacy concerns

The privacy risks of sharing your DNA with consumer genetic-testing companies are not well understood by consumers. While these companies do have an incentive to be on the consumer's side, there are still thorny issues related to genetic privacy that don't have easy answers or iron-clad legislative protections.

Data Collection and Sharing

Direct-to-consumer genetic testing companies collect a wide variety of personal data, including basic identifiers like your address and email address, and, in some cases, facts about your family and your health. This data is often shared with third parties, including well-known companies such as Google, Microsoft, Facebook, and Yahoo, as well as lesser-known data collecting companies. This data can be used to build profiles of individual consumers and to target them with advertising. While these practices are common across the web, the information collected by genetic testing companies can be particularly sensitive.

Research Permissions

Genetic testing companies often allow customers to opt into "research" conducted with their DNA data. However, this research may not always be the kind of altruistic research customers imagine. In some cases, it could mean internal research intended for product development for the company itself. Additionally, the permissions granted when consumers opt into research are likely more expansive than consumers realize, as they often include permission for third-party researchers to receive not just de-identified DNA information but any other information the company collects about you, including self-reported health information and information about relatives.

Data Security

There is also a risk of data breaches and hacks, as has happened with several genetic testing companies in the past. In 2018, DNA testing site MyHeritage suffered a breach of 92 million usernames and passwords. In 2019, attackers gained access to a trove of data from Veritas Genetics. And in 2020, GEDmatch was hacked, resulting in more than a million profiles—most of which had opted out and should have been hidden—becoming available for police to search. Once your DNA is on the dark web, it's out there for good.

Law Enforcement and Government Access

Another concern is that law enforcement and government agencies may pressure genetic testing companies to share your DNA data. This has already happened in the case of the Golden State Killer, where law enforcement used a relative's DNA to identify the suspect. While genetic testing companies may resist these requests, there are no guarantees that they will be able to protect your data from subpoenas or warrants.

Insurance Discrimination

In the United States, the Genetic Information Nondiscrimination Act (GINA) prevents health insurers from using DNA information to discriminate, but the law does not apply to life insurance. This means that life insurance companies may deny coverage or charge higher rates based on genetic information. While some states have enacted laws to protect against genetic discrimination in life insurance, most states do not have any protections in place.

DNA testing kits and their accuracy

The accuracy of DNA testing kits depends on several factors, including the quality of the test, the interpretation of the results, and the purpose for which the test is used.

Firstly, it is important to note that there are different types of DNA tests available, such as direct-to-consumer (DTC) genetic tests and tests ordered by medical providers. DTC tests are often used to explore ancestry or genealogy, while tests ordered by medical providers are typically used as diagnostic tools for health conditions. The accuracy of these tests can vary due to differences in testing methods and the interpretation of results.

In terms of accuracy, there have been concerns about the reliability of DTC genetic testing kits. A 2018 study found that 40% of gene variants identified by DTC kits were false positives. Additionally, some genetic variants classified as "increased risk" by DNA companies were deemed benign or common by clinical labs. These discrepancies may be due to errors in genotyping arrays or differences in the interpretation of results.

When it comes to ancestry testing, companies like 23andMe and AncestryDNA compare an individual's DNA to reference groups with known ancestries. However, these reference groups are constantly changing and may not always be accurate, especially for individuals from minority backgrounds. As a result, ancestry estimates can vary between companies and may not provide a precise representation of an individual's ancestral makeup.

It is worth noting that DNA testing kits have improved over time, and companies are continually working to enhance their accuracy. However, it is essential to recognize that these tests provide probabilistic information rather than definitive answers. For example, even if an individual carries a gene variant associated with a particular condition, it does not guarantee that they will develop that condition.

In the context of life insurance, the accuracy of DNA testing kits is crucial. Life insurance companies are interested in genetic tests that are ordered by medical providers and included in an individual's medical records. They may also consider at-home genetic tests if the results include a recommendation to consult a doctor or if the results impact the individual's family medical history. However, life insurance companies generally do not consider at-home DNA tests to be reliable for assessing mortality or health risks.

In summary, while DNA testing kits have become increasingly popular, their accuracy varies depending on the test type, testing methods, and interpretation of results. It is important for consumers to understand the limitations of these tests and seek appropriate guidance when interpreting their results, especially when making decisions related to health or life insurance.

The Genetic Information Nondiscrimination Act (GINA)

While GINA provides protection for consumers in the health insurance sector, it is important to note that state laws vary when it comes to life insurance. As of 2004, some countries had established moratoria on the use of genetic information by insurers, either full or partial. In the US, there is no federal legislation directly addressing this issue, and state laws differ significantly. A few states bar the use of genetic test results, while others prohibit decisions based on genetic information for specific conditions. Some states only require informed consent for genetic testing or mandate that underwriting decisions reflect actual risk.

The impact of GINA on the insurance industry and consumers is complex. On the one hand, GINA protects individuals from discrimination based on their genetic information when it comes to health insurance. On the other hand, the lack of federal legislation regarding life insurance means that consumers' genetic information may be used by life insurance companies to make decisions about coverage and rates. This can lead to concerns about privacy and potential discrimination.

To address these concerns, some states have proposed or enacted genetic privacy laws. For example, Florida has enacted a law that prohibits life insurance companies from using genetic information to cancel, limit, or deny coverage or set different premium rates. California's Genetic Information Privacy Act (GIPA) also prohibits direct-to-consumer companies from disclosing genetic information to companies administering certain types of insurance, including life insurance.

The debate around the use of genetic information by life insurance companies is ongoing, and it is clear that GINA has a limited scope in this regard. While GINA provides important protections in the health insurance sector, it does not extend to life insurance, leaving consumers potentially vulnerable to the use of their genetic information by life insurers.

State laws and their variations

State laws regarding the use of DNA information by life insurance companies vary across the United States. While there is federal legislation in the form of the Genetic Information Nondiscrimination Act (GINA), which prevents genetic discrimination in the health insurance sector, there is no federal law that limits the use of genetic information by life insurance companies.

Currently, 17 states have laws that restrict life insurers from using genetic information in the underwriting process. These laws go beyond GINA by prohibiting life insurers from requesting, requiring, or using genetic information to make decisions about eligibility, premium rates, and coverage terms. However, life insurers argue that these laws can be interpreted differently and that there are no state laws barring them from using existing DNA results.

In contrast, only two states prohibit requiring an applicant to take a genetic test for life insurance. If an individual does not disclose their genetic information, life insurers claim they have "the right to void a policy."

Some states have taken additional steps to protect consumer genetic information. For example, Florida has enacted a genetic privacy law that prohibits life insurance companies from using genetic information to cancel, limit, or deny coverage or set different premium rates. Meanwhile, California's Genetic Information Privacy Act (GIPA) prohibits direct-to-consumer companies from disclosing genetic information to any company responsible for administering life insurance.

On the other hand, some states have relatively weak protections or none at all. For instance, Vermont bars the use of genetic test results, while North Carolina prohibits decisions based on genetic information regarding specific conditions like sickle-cell trait. New York requires informed consent for genetic testing, and Wisconsin mandates that underwriting decisions reflect actual risk.

The variation in state laws regarding the use of DNA information by life insurance companies underscores the ongoing debate and the need for further regulation to protect consumer privacy and prevent discrimination.

The ethics of privacy

The use of DNA information by life insurance companies raises important ethical concerns regarding privacy. While consumers may benefit from knowing their genetic risks, there are risks associated with sharing this information with insurers.

The Right to Privacy

For policymakers, the issue is clear: genetic information is highly personal and private. Using it to determine insurance rates is a breach of privacy and will lead to inequity in the insurance market. This view is supported by consumer privacy experts and watchdogs, who argue that regulations are needed to protect individuals' privacy and prevent discrimination.

The Impact on Insurance Rates

Insurers, on the other hand, argue that they need access to this information to accurately assess risk and set rates. Without it, they may be at a disadvantage, as consumers with genetic predispositions to certain diseases may be more likely to buy insurance without disclosing this information. This could lead to "adverse selection" and an uneven playing field, with high-risk individuals paying disproportionately high rates.

The Potential for Discrimination

There is a valid concern that individuals with genetic predispositions to certain diseases may be discriminated against and denied coverage or charged higher premiums. This could create a "ghetto of the uninsured," as those with genetic risk factors are deemed too high-risk to insure. This could particularly impact individuals with rare diseases linked to single genes, as well as those with risk factors for more common diseases such as heart disease and diabetes.

The Impact on Medical Testing and Treatment

The potential for discrimination based on genetic information may deter individuals from seeking medical testing and treatment. This could have negative consequences for their health and well-being, as early detection and treatment can improve outcomes for many conditions.

The Need for Regulation

The Genetic Information Nondiscrimination Act (GINA) in the US prohibits health insurers from using genetic information to make coverage decisions, but it does not extend to life, long-term care, or disability insurance. This has led to a situation where individuals can be denied coverage or charged higher rates based on their genetic risk factors. While some states have enacted additional protections, there is no federal law specifically addressing the use of genetic information by life insurers. This has resulted in a patchwork of state laws, with varying levels of protection for consumers.

The Way Forward

Several potential solutions have been proposed to address these ethical concerns. One option is to ban the use of genetic tests by insurers altogether, but this could lead to higher rates for all consumers if those at higher risk disproportionately purchase insurance. Another approach is to allow insurers to access only certain defined sets of high-risk genes and variants, with rates modified for individuals who take effective measures to reduce their risk. Providing a modest amount of insurance to everyone, with additional coverage available to those who consent to genetic testing, is another possible solution. Ultimately, the decision of how to balance the need for privacy with the need for accurate risk assessment in the insurance industry is a complex and ongoing debate.

Frequently asked questions